Business
Everest Medicines Signs Share Purchase Agreement with Hasten Biopharmaceuticals (Asia) Limited
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that its wholly-owned subsidiary, EverSea Medicines (Singapore) Pte. Ltd., has entered into a Share Purchase Agreement with Hasten Biopharmaceuticals (Asia) Limited to conditionally acquire the entire equity interest in its wholly-owned subsidiary, Hasten Biopharmaceuticals (SG)
About this update from Everest Medicines Ltd.
[{"type":"list","items":[{"val":[{"type":"text","content":"Accelerates Asia Pacific expansion by acquiring a ready-built regional commercial platform with 14 marketed chronic disease products","length":132,"tagName":"p"}]},{"val":[{"type":"text","content":"Aggregate consideration of USD250,000,000 (approximately RMB1,721,650,000), payable in three installments","length":105,"tagName":"p"}]},{"val":[{"type":"text","content":"Delivers near-term revenue and profitability with 2025 normalized revenue of US$82,232,000 (approximately RMB566,299,000) with an EBITDA of US$27,273,000 (approximately RMB187,818,000).","length":185,"tagName":"p"}]},{"val":[{"type":"text","content":"Strong synergies with Everest's existing portfolio and enhances Everest's position as a regional partner of choice for Chinese and global innovative assets","length":163,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":585,"olType":false},{"type":"text","content":"SHANGHAI, April 8, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that its wholly-owned subsidiary, EverSea Medicines (Singapore) Pte. Ltd., has entered into a Share Purchase Agreement with Hasten Biopharmaceuticals (Asia) Limited to conditionally acquire the entire equity interest in its wholly-owned subsidiary, Hasten Biopharmaceuticals (SG) Pte. Ltd.","length":569,"tagName":"p"},{"type":"text","content":"The Acquisition will complement the Company's existing pipeline, unlock significant synergies between its product portfolio and commercialization capabilities, strengthen its business profile, deepen its presence in strategically aligned markets, and further expand its scale and breadth of its business across the Asia Pacific region.","length":339,"tagName":"p"},{"type":"text","content":"According to the agreement:","length":27,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The aggregate consideration is USD250,000,000 (approximately RMB1,721,650,000), payable in three installments. The first installment of USD150,000,000 (approximately RMB1,032,990,000), representing 60% of the consideration, payable at Closing, subject to the satisfaction or waiver of the condition...